{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:44:26Z","timestamp":1791477866054,"version":"4.3.4"},"reference-count":53,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T00:00:00Z","timestamp":1622678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Influenza Resp Viruses"],"published-print":{"date-parts":[[2021,11]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Standard\u2010dose seasonal influenza vaccines often produce modest immunogenic responses in adults \u226565\u00a0years old. MF59 is intended to elicit a greater magnitude and increased breadth of immune response.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the effectiveness of seasonal MF59\u2010adjuvanted trivalent\/quadrivalent influenza vaccine (aTIV\/aQIV) relative to no vaccination or vaccination with standard or high\u2010dose egg\u2010based influenza vaccines among people \u226565\u00a0years old.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Cochrane methodological standards and PRISMA\u2010P guidelines were followed. Real\u2010world evidence from non\u2010interventional studies published in peer\u2010reviewed journals and gray literature from 1997 through to July 15, 2020, including cluster\u2010randomized trials, were eligible. Two reviewers independently extracted data; risk of bias was assessed using the ROBINS\u2010I tool.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Twenty\u2010one studies conducted during the 2006\/07\u20132019\/20 influenza seasons were included in the qualitative review; 16 in the meta\u2010analyses. Meta\u2010analysis of test\u2010negative studies found that aTIV reduced medical encounters due to lab\u2010confirmed influenza with pooled estimates of 40.7% (95% CI: 21.9, 54.9;\n I<\/jats:italic>\n 2<\/jats:sup>\n \u00a0=\u00a00%) for non\u2010emergency outpatient visits and 58.5% (40.7, 70.9;\n I<\/jats:italic>\n 2<\/jats:sup>\n \u00a0=\u00a052.9%) for hospitalized patients. The pooled estimate of VE from case\u2010control studies was 51.3% (39.1, 61.1;\n I<\/jats:italic>\n 2<\/jats:sup>\n \u00a0=\u00a00%) against influenza\u2010 or pneumonia\u2010related hospitalization. The pooled estimates for the relative VE of aTIV for the prevention of influenza\u2010related medical encounters were 13.9% (4.2, 23.5;\n I<\/jats:italic>\n 2<\/jats:sup>\n \u00a0=\u00a095.9%) compared with TIV, 13.7% (3.1, 24.2;\n I<\/jats:italic>\n 2<\/jats:sup>\n \u00a0=\u00a098.8%) compared with QIV, and 2.8% (\u22122.9, 8.5;\n I<\/jats:italic>\n 2<\/jats:sup>\n \u00a0=\u00a094.5%) compared with HD\u2010TIV.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Among adults \u226565\u00a0years, aTIV demonstrated significant absolute VE, improved relative VE compared to non\u2010adjuvanted standard\u2010dose TIV\/QIV, and comparable relative VE to high\u2010dose TIV.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/irv.12871","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T07:21:32Z","timestamp":1622791292000},"page":"813-823","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":109,"title":["Effectiveness of the MF59\u2010adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7144-4827","authenticated-orcid":false,"given":"Brenda L.","family":"Coleman","sequence":"first","affiliation":[{"name":"Sinai Health Toronto ON Canada"},{"name":"Dalla Lana School of Public Health Toronto ON Canada"},{"name":"Western University London ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Sanderson","sequence":"additional","affiliation":[{"name":"Sinai Health Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mendel D. M.","family":"Haag","sequence":"additional","affiliation":[{"name":"Seqirus Netherlands B.V Amsterdam the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"McGovern","sequence":"additional","affiliation":[{"name":"Seqirus Inc Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Global influenza strategy 2019\u20132030","author":"World Health Organization","year":"2019"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.10.040"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis211"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-020-05167-4"},{"issue":"33","key":"e_1_2_9_6_1","first-page":"1057","article-title":"Estimates of deaths associated with seasonal influenza \u2013 United States, 1976\u20132007","volume":"59","author":"Centres for Disease Control and Prevention","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.307.6910.988"},{"issue":"47","key":"e_1_2_9_8_1","first-page":"461","article-title":"Vaccines against influenza WHO position paper \u2013 November 2012","volume":"87","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70295-X"},{"issue":"2","key":"e_1_2_9_10_1","first-page":"Cd004876","article-title":"Vaccines for preventing influenza in the elderly","volume":"2","author":"Demicheli V","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2017.09.010"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2014.03.008"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13249"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.07.027"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.12.090"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002336"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.07.013"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.04.030"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.12.011"},{"key":"e_1_2_9_20_1","volume-title":"Effectiveness of the MF59\u2010adjuvanted trivalent or quadrivalent seasonal influenza vaccine (FLUAD) among adults aged 65 or older, a systematic review and meta\u2010analysis","author":"Coleman BL","year":"2020"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_2_9_22_1","unstructured":"GRADE working group.GRADE handbook: handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. In: Sch\u00fcnemann H Bro\u017cek J Fuyatt G Oxman A editors.;2013."},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002742"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.09.069"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1627206"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1688151"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.10.032"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.10.071"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.07.059"},{"key":"e_1_2_9_31_1","doi-asserted-by":"crossref","unstructured":"Van BuynderP KonradS Van BuynderJ RamlerG.The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine in the elderly [poster]. OPTIONS VIII. Cape Town SA:2013b.","DOI":"10.1016\/j.vaccine.2013.07.059"},{"key":"e_1_2_9_32_1","unstructured":"2020 Public Health England London GB Public Health England IS Section Surveillance of influenza and other respiratory viruses in the UK: winter 2019 to 2020 69"},{"key":"e_1_2_9_33_1","unstructured":"2019 Public Health England London England Public Health England Immunisation and Countermeasures Division NIS Public Health England Surveillance of influenza and other respiratory viruses in the UK: winter 2018 to 2019 57"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.07.017"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.08.039"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.22231"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.07.077"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1622418"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2020.1750380"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy716"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa080"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kws313"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030344"},{"key":"e_1_2_9_44_1","unstructured":"vanAalstR.Relative VE of HD vs adjuvanted influenza vaccine: a retrospective cohort study [abstract 10499]. OPTIONS X. Signapore;2019."},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030446"},{"key":"e_1_2_9_46_1","unstructured":"DivinoV Mould\u2010QuevedoJ DeKovenM JiangM KrishnarajahG.Hospitalization encounters following vaccination with adjuvanted trivalent influenza vaccine compared to egg\u2010based trivalent high\u2010dose egg\u2010based quadrivalent and trivalent vaccines among the US elderly using claims data [poster]. OPTIONS X. Singapore.2019a."},{"key":"e_1_2_9_47_1","unstructured":"DivinoV Mould\u2010QuevedoJ JiangM DeKovenM KrishnarajahG.Real\u2010world outcomes of adjuvanted trivalent influenza vaccine compared to egg\u2010based trivalent high\u2010dose egg\u2010based quadrivalent and trivalent vaccines among the US elderly during 2016\u20132018 flu seasons using claims data [poster]. OPTIONS X; Singapore.2019b."},{"key":"e_1_2_9_48_1","unstructured":"BoikosC FischerL O'BrienD VaseyJ SylvesterG MansiJ.Relative effectiveness of aTIV versus TIVe QIVe and HD\u2010TIV in preventing influenza\u2010related medical encounters during the 2017\u20132018 and 2018\u20132019 influenza seasons in the US [poster]. National Foundation for Infectious Diseases. Virtual:2020."},{"key":"e_1_2_9_49_1","unstructured":"McConeghyKW DavidsonHE HanL et al.Can adjuvanted influenza vaccine given as standard of care reduce the risk for influenza outbreaks in nursing homes: evidence from a cluster\u2010randomized trial of 823 nursing homes [abstract]. European Congress of Clinical Microbiology and Infectious Diseases. Virtual.2020."},{"key":"e_1_2_9_50_1","volume-title":"Effectiveness of adjuvanted vs. non\u2010adjuvanted influenza vaccine in US nursing homes [poster]","author":"Gravenstein S","year":"2019"},{"key":"e_1_2_9_51_1","first-page":"S296","volume-title":"A cluster\u2010randomized trial of adjuvanted trivalent influenza vaccine vs. standard dose in US nursing homes [abstract]","author":"Gravenstein S","year":"2018"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.09.105"},{"key":"e_1_2_9_53_1","unstructured":"BoikosC.Poster clarification [email]. In: Coleman BL ed.2020."},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0199180"}],"container-title":["Influenza and Other Respiratory Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/irv.12871","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/irv.12871","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/irv.12871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T23:15:22Z","timestamp":1693178122000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/irv.12871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1111\/irv.12871"],"URL":"https:\/\/doi.org\/10.1111\/irv.12871","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/IRV.12871\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.12871\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/IRV.12871\/v2\/response1","asserted-by":"object"}]},"ISSN":["1750-2640","1750-2659"],"issn-type":[{"value":"1750-2640","type":"print"},{"value":"1750-2659","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,3]]},"assertion":[{"value":"2021-04-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}